论文部分内容阅读
目的 观察血清 CYFRA2 1- 1水平的变化来探讨 CT引导下经皮肺穿刺锚状电极高温射频消融治疗非小细胞肺癌的近期疗效 .方法 分别在手术切除射频治疗前 1d,治疗后10 ,2 0和 30 d采集非小细胞肺癌 (NSCL C)患者血清标本 89例 ,其中手术组 41例 ,射频治疗组 48例 ,采用放射免疫法测定血清样本中 CYFRA2 1- 1表达水平 .结果 非小细胞肺癌患者血清 CYFRA2 1- 1在治疗前总体表达水平 (12 .98±7.34 )μg· L- 1 鳞癌患者为 (2 0 .48± 11.2 3)μg· L- 1 、腺癌为(5 .48± 3.42 )μg· L- 1 ,鳞癌患者显著高于腺癌患者 (P<0 .0 5 ) .血清 CYFRA2 1- 1在治疗后 10 d手术组显著下降 (P<0 .0 5 ) ,射频治疗组 10 d后无明显变化 ,30 d后显著下降 (P<0 .0 5 ) ,手术组和射频治疗组比较无明显差异 (P>0 .0 5 ) .结论 射频消融治疗非小细胞肺癌近期疗效明显 ,且操作简便、创伤小、恢复快、可反复多次治疗 ,对患者身体条件要求不高 ,具有很好的临床应用前景
Objective To observe the changes of serum CYFRA2 1-1 in CT-guided high-temperature radiofrequency catheter ablation of non-small cell lung cancer with radiofrequency catheter ablation.Methods One week before radiofrequency ablation, And serum samples of non-small cell lung cancer (NSCL C) were collected from 30 patients for 30 days, including 41 cases in operation group and 48 cases in radiofrequency ablation group.The serum levels of CYFRA2 1- 1 in serum samples were determined by radioimmunoassay.Results Non-small cell lung cancer The serum level of CYFRA2 1- 1 before treatment was (12.98 ± 7.34) μg · L-1 in squamous cell carcinoma (20.48 ± 11.23) μg · L- 1 and in adenocarcinoma was (5.48 ± 3.42) μg · L-1, significantly higher in patients with squamous cell carcinoma than in patients with adenocarcinoma (P <0.05) .Serum CYFRA2-1 decreased significantly in the 10-day group after operation (P <0.05) Radiofrequency ablation did not change significantly after 10 days, and then decreased significantly after 30 days (P <0.05). There was no significant difference between the radiotherapy group and the radiotherapy group (P> 0.05) Short-term effect of lung cancer is obvious, and the operation is simple, less trauma, rapid recovery, repeated multiple treatments, the patient’s physical condition Demand is not high, with good prospects for clinical application